International Myeloma Workshop | Conference

Luciano Costa, MD, PhD, Discusses Lessons Learned From the COVID-19 Pandemic in the Treatment of Myeloma
October 23, 2021

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to highlight key lessons that COVID-19 pandemic taught him.

Luciano Costa, MD, PhD, Discusses How his Institution Handled the COVID-19 Pandemic
October 20, 2021

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic affected his work and how they adapted.

Luciano Costa, MD, PhD, Shares Key Takeaways From the MASTER Trial in Multiple Myeloma
October 19, 2021

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.

Fredrik Schjesvold, MD, PhD, Discusses the Potential of Minimal Residual Disease –Directed Treatment for Multiple Myeloma
October 15, 2021

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.

Luciano Costa, MD, PhD, Discusses Implications From The MASTER Trial in Newly Diagnosed Multiple Myeloma
October 09, 2021

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss key implications from the phase 2 MASTER trial, utilizing daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Fredrik Schjesvold, MD, PhD, Discusses Adjustments in the Treatment of Myeloma During the COVID-19 Pandemic
October 07, 2021

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic impacted the care of multiple myeloma at the Oslo Myeloma Center .

Fredrik Schjesvold, MD, PhD, Discusses the Implications of an FDA Approval for Melflufen in Transplant-Naïve Relapsed/Refractory Multiple Myeloma
October 03, 2021

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how he would like to see the OCEAN trial and Melflufen progress for relapsed/refractory multiple myeloma.

Luciano Costa, MD, PhD, Discusses the Safety Profile of Dara-KRd From the MASTER Trial in Newly Diagnosed Multiple Myeloma
October 02, 2021

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most common adverse effects experienced from the quadruplet drug treatment for patients with multiple myeloma.

Fredrik Schjesvold, MD, PhD, Discusses the Safety Profile of Melflufen/Dexamethasone in Relapsed/Refractory Multiple Myeloma
October 01, 2021

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss the differences in safety profiles between melflufen/dexamethasone and pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Fredrik Schjesvold, MD, PhD, Discusses the Importance of Subgroups When Utilizing Melflufen/Dexamethasone in Relapsed/Refractory Multiple Myeloma
September 30, 2021

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about importance of subgroups when administering melflufen and dexamethasone to patients with relapsed/refractory multiple myeloma.